{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:16:59Z","timestamp":1765232219132,"version":"3.40.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N N405 671540"],"award-info":[{"award-number":["N N405 671540"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ejmech.2014.12.041","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T16:48:19Z","timestamp":1419439699000},"page":"202-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: Design, synthesis, and antidepressant properties. Part II"],"prefix":"10.1016","volume":"92","author":[{"given":"Vittorio","family":"Canale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Kurczab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagna","family":"Witek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Paw\u0142owski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Zajdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2014.12.041_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","article-title":"Functional, molecular and pharmacological advances in 5-HT7 receptor research","volume":"25","author":"Hedlund","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2014.12.041_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12035-011-8175-3","article-title":"Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives","volume":"43","author":"Mathis","year":"2011","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neuropharm.2004.11.015","article-title":"Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression","volume":"48","author":"Guscott","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2014.12.041_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2006.10.001","article-title":"Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice","volume":"555","author":"Weso\u0142owska","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/joim.12113","article-title":"Developing new pharmacotherapies for autism","volume":"274","author":"Ecker","year":"2013","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ejmech.2014.12.041_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tips.2012.09.004","article-title":"Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders","volume":"33","author":"Spooren","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2014.12.041_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejpain.2011.07.004","article-title":"Role of peripheral versus spinal 5-HT(7) receptors in the modulation of pain undersensitizing conditions","volume":"16","author":"Brenchat","year":"2012","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejmech.2014.12.041_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1515\/revneuro-2014-0009","article-title":"Selective agonist for serotonin 7 (5-HT7) receptor and their applications in preclinical models: an overview","volume":"25","author":"Di Pilato","year":"2014","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2014.12.041_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.biopsych.2012.06.008","article-title":"Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild type and Fmr1 knockout mice, a model of Fragile X syndrome","volume":"72","author":"Costa","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2014.12.041_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/0929867023371030","article-title":"Arylpiperazine derivatives acting at 5-HT(1A) receptors","volume":"9","author":"Lopez-Rodriguez","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2014.09.070","article-title":"Structure-affinity\/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at \u03b11 and 5-HT1A receptors","volume":"87","author":"Franchini","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib12","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1016\/j.bmcl.2006.04.035","article-title":"Arylpiperazines with N-Acylated amino acids as 5-HT1A receptor ligands","volume":"16","author":"Zajdel","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.12.041_bib13","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.bmc.2007.02.018","article-title":"Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in\u00a0vivo pharmacological evaluation","volume":"15","author":"Zajdel","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib14","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1016\/j.bmc.2005.01.060","article-title":"Parallel solid-phase synthesis and characterization of new sulfonamide and carboxamide proline derivatives as potential CNS agents","volume":"13","author":"Zajdel","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejmech.2014.03.005","article-title":"Solid-supported synthesis, molecular modeling, and biological activity of long-chain arylpiperazine derivatives with cyclic amino acid amide fragments as 5-HT7 and 5-HT1A receptor ligands","volume":"78","author":"Canale","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib16","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1021\/jm060300c","article-title":"Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity","volume":"49","author":"Ko\u0142aczkowski","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib17","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/jm800176x","article-title":"Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothaizole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands","volume":"51","author":"Siracusa","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2012.11.042","article-title":"Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A\/5-HT2A\/5-HT7 and dopamine D2\/D3 receptors","volume":"60","author":"Zajdel","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","article-title":"5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception","volume":"158","author":"Martel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-3565(24)37821-8","article-title":"Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation","volume":"287","author":"Adham","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2014.12.041_bib21","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2014.12.041_bib22","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1021\/jm3003679","article-title":"Investigation on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin 5-HT(7) receptor with agonist or antagonist action in\u00a0vitro or ex\u00a0vivo","volume":"55","author":"Lacivita","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib23","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1021\/jm070487n","article-title":"Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazine hexanamides, a class of 5-HT7 receptor agents","volume":"50","author":"Leopoldo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.12.041_bib24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin 5-HT1A receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2014.12.041_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.neuropharm.2006.04.017","article-title":"Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression","volume":"51","author":"Weso\u0142owska","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2014.12.041_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-2836(77)80200-3","article-title":"The protein data bank: a computer-based archival file for macromolecular structures","volume":"112","author":"Bernstein","year":"1977","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib27","unstructured":"Discovery Studio v.3.5, Accelrys Software, Inc. San Diego, CA."},{"key":"10.1016\/j.ejmech.2014.12.041_bib28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"\u0160ali","year":"1993","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res."},{"year":"2014","series-title":"Canvas, Version 2.0","key":"10.1016\/j.ejmech.2014.12.041_bib30"},{"year":"2014","series-title":"LigPrep, Version 3.0","key":"10.1016\/j.ejmech.2014.12.041_bib31"},{"year":"2014","series-title":"Schr\u00f6dinger Release 2014-2: Epik, Version 2.8","key":"10.1016\/j.ejmech.2014.12.041_bib32"},{"year":"2014","series-title":"Glide, Version 6.3","key":"10.1016\/j.ejmech.2014.12.041_bib33"},{"key":"10.1016\/j.ejmech.2014.12.041_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev.pharmtox.42.091101.144224","article-title":"The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop","volume":"42","author":"Shi","year":"2002","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2014.12.041_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/prot.10286","article-title":"Structure validation by Calpha geometry: phi, psi and Cbeta deviation","volume":"50","author":"Lovell","year":"2003","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2014.12.041_bib36","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414011507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414011507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:06:35Z","timestamp":1747310795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523414011507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":36,"alternative-id":["S0223523414011507"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.12.041","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: Design, synthesis, and antidepressant properties. Part II","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.12.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}